1. A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes

   • Maia van Kan
   • Kathryn E. Burns
   • Nuala A. Helsby

   Review Article 04 August 2021 Pages: 755 - 769

   

2. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update

   • Zahra Torki
   • Davood Ghavi
   • Mohammad Reza Alivand

   Review Article 12 September 2021 Pages: 771 - 793

   

3. Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors

   • Shengfu Wang
   • Chunyan Wang
   • Shangxue Yan

   Original Article 26 July 2021 Pages: 795 - 804

   

4. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

   • Sema Sezgin Göksu
   • Ali Murat Tatlı
   • Hasan Şenol Coşkun

   Original Article 26 July 2021 Pages: 805 - 812

   

5. Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy

   • Goretti Duran
   • Raquel Cruz
   • María Jesús Lamas

   Original Article 26 July 2021 Pages: 813 - 823

   

6. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

   • Mehmet Akce
   • Anthony El-Khoueiry
   • Cindy L. O’Bryant

   Original Article Open access 29 July 2021 Pages: 825 - 836

   

7. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon

   • Marianne Rodrigues Fernandes
   • Juliana Carla Gomes Rodrigues
   • Ney Pereira Carneiro dos Santos

   Original Article 31 July 2021 Pages: 837 - 844

   

8. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells

   • Marielle Huot
   • Maxime Caron
   • Noël J. M. Raynal

   Original Article 31 July 2021 Pages: 845 - 856

   

9. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease

   • Toshihito Otani
   • Kakuhiro Yamaguchi
   • Noboru Hattori

   Original Article 04 August 2021 Pages: 857 - 865

   

10. Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models

    • Ivan N. Terterov
    • Vyacheslav A. Chubenko
    • Alexey A. Bogdanov

    Original Article 05 August 2021 Pages: 867 - 878

    

11. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects

    • Vladimir Hanes
    • Vincent Chow
    • Adeep Puri

    Original Article Open access 05 August 2021 Pages: 879 - 886

    

12. A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

    • Mingxiang Liao
    • Krzysztof G. Jeziorski
    • Jim J. Xiao

    Original Article Open access 09 August 2021 Pages: 887 - 897

    

13. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials

    • Hong Xiang
    • Lucy Liu
    • Helen Collins

    Original Article Open access 12 August 2021 Pages: 899 - 910

    

14. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study

    • Linea Natalie Toksvang
    • Liv Andrés-Jensen
    • Kjeld Schmiegelow

    Short Communication 18 June 2021 Pages: 911 - 917

    

15. Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”

    • Wing H. Tong

    Letter to the Editor 01 September 2021 Pages: 919 - 920